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of the phantom are obtained at beam axis entrance and exit, 
as well as laterally. Dose distributions for two patients are 
calculated for clinical plans involving 6 MV and 15 MV photon 
beams and field-in-field techniques. Three volumes are 
studied, namely, PTV (516 cm3) and CTVT (10 cm3) for 
patient one, and PTVT (117 cm3) for patient two. 
Calculations in the case of phantom and patient geometries 
are performed by Eclipse AAA and Acuros XB algorithms and 
by Oncentra CC algorithm. Corresponding Monte Carlo dose 
calculations are carried out using EGSnrc/BEAMnrc software. 
Estimates like D98% (dose to 98% of the volume) and V95% 
(the volume receiving 95% of the dose) are used when 
comparing the dose distributions. The accuracy of the 
different algorithms when including a bolus is investigated. 
 
Results: Measurements in the phantom case show a negligible 
dose decrease at the phantom-in-air interface but more than 
10% dose decrease at this interface laterally or at beam exit. 
Large uncertainties in calculated data are detected in the 
interface regions, namely up to 4 mm depth from the 
phantom-air interface and 2 mm depth from the phantom-in-
air interface. In the patient cases, deviations less than 3% are 
observed for PTV and CTVT for the dosimetry parameters 
D98% D2% and V105% obtained by the different algorithms 
and the Monte Carlo method. For PTVT, the largest 
deviations are between AAA and Monte Carlo data, for 
example, 3.6% for D98% and 9.2 % for V105%. The results are 
explained by the fact that PTV is large and eventual 
uncertainties at the boundary has smaller effect on the dose 
volume histograms. CTVT is small, however, the distance 
from the CTVT contour to the surface and to the lung 
interface is 4 mm or more at each slice. In the third case, a 
large partial volume of PTVT is located near the lung 
interface where the dose uncertainties are large. 
Furthermore, it has been found, that the algorithms reflect 
properly the dose changes due to bolus except for AAA, 
where the dose volume histograms for CTVT obtained with 
and without bolus can’t be distinguished. 
 
Conclusion: Partial volume located near the lung interface 
has major effect on target coverage. The measured dose 
decrease and the uncertainties of the treatment planning 
algorithms near interfaces should be taken into account when 
establishing guidelines for target delineation and coverage 
for patients with thin chest wall. 
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Purpose or Objective: The Hi-Art Helical TomoTherapy unit 
is a linear accelerator equipped with an on-board CT detector 
array. It delivers radiation in a helical fashion with daily CT 
imaging for image guidance and beam monitoring. In vivo 
dosimetry is a recommended part of treatment with the 
potential of improving patient safety. Conventional 
approaches of in vivo dosimetry cannot be implemented for 
TomoTherapy due to the rotational nature of the system and 
thus transit dosimetry is required. This study has investigated 
the use of the detector sinogram in performing transit 
dosimetry by modelling how the primary photons are 
influenced by scatter geometry for a static and helical field. 
The aim has been to produce a semi-empirical model of the 
exit detector signal and investigate factors that influence the 
signal at the imaging panel of a TomoTherapy unit.  
 
Material and Methods: The detector signal profile (detector 
sinogram) is extracted for the DICOM data for each 
procedure. It contains the response at each detector channel 
and for each projection. The exit detector response for an 
open field is measured in-air with a moving couch for a static 
and helical delivery. The exit detector sinogram for an in-air 
measurement has been used as an input into a signal 
reconstruction model of the exit detector sinogram when a 
scattering medium is positioned on the couch. A simple ray-
tracing model has been produced using narrow beam 
conditions for the attenuation of the beam in a cylindrical, 
uniform phantom (Tomo® Cheese Phantom). The model relies 
on TPR data previously determined in the department as 
shown in Thomas et al., (2012).  
 
Results: The simulated sinogram agrees with the measured 
sinogram for both the static and helical deliveries within ± 
10% in the central region of the phantom. At the edge of the 
phantom this increases to ±15% due to set-up issues. 
 
 
Figure 1 shows a single projection (7 degrees) taken from the 
sinogram data for the measured and modeled exit detector 
sinograms. 
 
Conclusion: At this stage of development, the model shows 
promise in use as an independent check tool. However, 
second order corrections, such as scatter, should be 
incorporated if the model is to be clinically used. Further 
work is also required to reduce set-up errors, i.e. by imaging 
the phantom prior to measurement. 
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Purpose or Objective: Compass© (IBA, Schwarzenbruck, 
Germany) is a 3D pre-treatment plan verification system. The 
linac fluence is measured with an ion chamber array (MatriXX 
(IBA)). Then via a detector fluence model and collapsed cone 
algorithm [1], the dose is calculated on the patient’s 
planning CT. It has been demonstrated that Compass can 
validate VMAT plans (73-99% gamma passing rate at 3%/3mm 
[2]) although it does introduce some dose blurring [3]. 
However, occasional failures do occur in plan verification 
using Compass (i.e. a significant variation on a DVH 
parameter or reduced gamma pass rate). The purpose of this 
work was to understand whether failures were due to genuine 
errors (such as treatment delivery or calculation) or due to 
the limitations and uncertainties of the Compass 
methodology. To achieve this, EBT3 film was used as best 
estimate of the true delivered dose distribution for prostate 
VMAT plans. 
 
Material and Methods: Six fields which were characteristic of 
segments from previously failed plans were measured with 
EBT3 film using advanced triple-channel dosimetry 
techniques (via FilmQAPro). These were then compared 
against Compass and the TPS (Pinnacle 9.8) doses using 
profile and 2D global gamma analysis. Twelve film 
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measurements were then acquired for 3 clinical prostate 
patients with Compass and film (one of which had failed 
Compass QC, likely due to narrow segments) in a solid water 
phantom and compared. 
 
Results: Profile analysis of the characteristic fields showed 
that for narrow but long fields on axis, the agreement 
between Compass and film was within 3%, slightly inferior to 
the TPS and film comparison at 2%. The worst case was 5% for 
a 1 x 10 cm off-axis field and 4% for irregular fields. The 
clinical films demonstrated that Compass accurately 
modelled dose distribution with 11/12 films achieving at least 
95% gamma passing at 3%/3mm with an average of 97.8 ± 2.1 
% (sd). The failed film achieved 93.6% passing. This was from 
the failed clinical plan – this is more likely due to the blurring 
induced by narrow segments than inaccurate delivery. Figure 
1 shows (a) an isodose for a passing film and (b) a profile 
taken across the film. All films passed when compared 
against the TPS (average gamma 98.3 ± 1.3 %).  
 
 
 
Figure 1. Representative film showing (a) an isodose and (b) a 
profile (dashed line on (a)) showing the Compass (thick) and 
film (thin) where 100% = 3.48 Gy. 
 
Conclusion: By comparison with film measurements, it has 
been shown that Compass is able to reproduce the dose 
distribution of clinical VMAT prostate plans, and is 
sufficiently accurate to detect any clinically relevant errors. 
However, users should be aware that the resolution of the 
Compass reconstruction algorithm is limited when narrow 
segments are predominant.  
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Purpose or Objective: New hybrid systems for patient 
specific pre-treatment QA are suited for 3D gamma (GA) and 
DVH reconstructed analysis (DA). For 2D evaluations, a 
3%/3mm agreement for 90-95% points is considered to be the 
state of art. Recent studies highlighted poor correlation 
between gamma passing rates and DVH clinical goals 
variations on PTV and OARs, so it could improve the situation 
to consider available DVH analysis tools. The aim of this work 
is to test the robustness and sensitivity of VMAT prostate 
patient specific DVH based acceptance criteria (AC) for QA 
using the COMPASS (Iba-Dosimetry) system in combination 
with the RayStation (Ray Search Laboratories) TPS. 
 
Material and Methods: For thirty prostate dual-arc VMAT 
plans, the most relevant DVH indices (DI) were considered for 
the PTV: D98, D95, D50, D1 and Dmean . Clinical doses were 
computed with both, COMPASS and RayStation, which share 
the same calculation algorithm. Plans were delivered with a 
VARIAN Trilogy equipped with a Millenium 120 MLC and 
measured with COMPASS. RayStation vs COMPASS 
reconstructed doses were analyzed in terms of DI differences. 
The AC rely on calculating mean values (m) and standard 
deviations (std) of DI differences and assigning for each DI 
difference a confidence interval equal to 1.5•std. To assess 
the AC robustness in terms of system sensitivity the TG119 
prostate case was optimized using a VMAT single arc 
technique. Three different types of errors were introduced 
individually in the RT-plan to mimic linac delivery 
inaccuracies: a) MU number modification (MU-error) from -3% 
to +4%, b) gantry angle shift (g-error) from 0° to 3° and c) 
widening of both leaf banks (w-error) from 0 to 2 mm. 
Modified plans were delivered and beforehand defined DI 
were calculated. 
 
Results: For RayStation vs COMPASS computed doses analysis 
DI differences < 0.4% have been found. In the TG119 plan PTV 
DI differences showed a linear trend respectively with MU-
errors (see figure) and g-errors. The proposed DVH based 
criteria detected MU-errors below -1.8% or above 1.3% and w-
errors > 1.5mm. The criteria led to the detecting of g-
errors>3°. 
 
 
 
